|
Development of transporter targeted platinum drugs for neuroblastoma
|
1R43CA174132-01
|
$172,738
|
$172,738
|
Mamelok, Richard
|
APRICITY THERAPEUTICS, INC.
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-23
|
$486,165
|
$9,723
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Improving T-cell therapies for neuroblastoma
|
5R01CA142636-03
|
$377,399
|
$377,399
|
DOTTI, GIANPIETRO
|
BAYLOR COLLEGE OF MEDICINE
|
|
Localization and Function of NKT Cells in Neuroblastoma
|
5R01CA116548-07
|
$234,457
|
$234,457
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S1
|
$41,433
|
$1,243
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S2
|
$75,000
|
$2,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-06
|
$2,934,758
|
$88,043
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
"Oncorequisite" Genes in MYC-mediated Transformation
|
4R00CA134743-03
|
$233,147
|
$46,629
|
FENG, HUI
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
3R01CA129377-05S1
|
$90,845
|
$90,845
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-05
|
$232,601
|
$232,601
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
|
5U54CA163117-02
|
$573,087
|
$418,354
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Biology and Therapy of High Risk Neuroblastoma
|
5P01CA081403-13
|
$2,006,380
|
$2,006,380
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome
|
5R33CA152809-03
|
$426,711
|
$426,711
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Role of gangliosides in tumor progression
|
5R01CA061010-17
|
$331,222
|
$82,806
|
LADISCH, STEPHAN
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Children's Oncology Group Chair's Grant
|
3U10CA098543-10S3
|
$176,626
|
$24,728
|
ADAMSON, PETER
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Children's Oncology Group Chair's Grant
|
7U10CA098543-10
|
$26,733,729
|
$3,742,722
|
ADAMSON, PETER
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Molecular Genetic Analysis of Human Neuroblastoma
|
5R01CA039771-24
|
$377,150
|
$377,150
|
BRODEUR, GARRETT
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Trk Expression and Inhibition in Human Neuroblastomas
|
5R01CA094194-10
|
$366,503
|
$366,503
|
BRODEUR, GARRETT
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Translational Genomics of MicroRNAs in Neuroblastoma
|
5K08CA136979-04
|
$161,773
|
$161,773
|
Cole, Kristina
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Copy number variations (CNVs) in neuroblastoma
|
4R00CA151869-03
|
$249,000
|
$249,000
|
DISKIN, SHARON
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-05
|
$602,864
|
$602,864
|
MARIS, JOHN
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-04
|
$331,098
|
$331,098
|
Mosse, YAEL
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Community Clinical Oncology Program Research Base
|
2U10CA095861-11
|
$1,608,610
|
$241,292
|
POLLOCK, BRAD
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
2U10CA045418-26
|
$1,423,934
|
$14,239
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
1U01CA168426-01
|
$1,211,593
|
$1,211,593
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet)
|
5U54CA121852-08
|
$1,743,884
|
$139,511
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-39S1
|
$140,000
|
$8,400
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-39S2
|
$75,000
|
$4,500
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-39
|
$3,816,425
|
$228,986
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbia University Medical Center Minority-Based Community Clinical Oncology Pro
|
1U10CA167791-01
|
$796,302
|
$23,889
|
GRANN, VICTOR
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
VEGF blockade and alternative angiogenic pathways in neuroblastoma
|
3R01CA124644-05S1
|
$37,627
|
$37,627
|
YAMASHIRO, DARRELL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
VEGF blockade and alternative angiogenic pathways in neuroblastoma
|
5R01CA124644-05
|
$324,053
|
$324,053
|
YAMASHIRO, DARRELL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-02
|
$363,125
|
$363,125
|
GEORGE, RANI
|
DANA-FARBER CANCER INSTITUTE
|
|
The Role of Stroma-derived Soluble TbetaRIII in Neuroblastoma
|
1F30CA168043-01
|
$47,232
|
$47,232
|
Knelson, Erik
|
DUKE UNIVERSITY
|
|
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma
|
5K08CA128925-06
|
$139,320
|
$139,320
|
Goldsmith, Kelly
|
EMORY UNIVERSITY
|
|
MDM2 regulates XIAP gene expression in cancer treatment
|
5R01CA123490-05
|
$249,581
|
$62,395
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Duluth Community Clinical Oncology Program
|
5U10CA035269-29
|
$538,966
|
$10,779
|
Nikcevich, Daniel
|
ESSENTIA INSTITUTE OF RURAL HEALTH
|
|
EORTC HEADQUARTERS
|
5U10CA011488-42
|
$235,448
|
$7,063
|
Lacombe, Denis
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Community Clinical Oncology Program: FL Pediatric CCOP
|
5U10CA035157-29
|
$443,765
|
$35,501
|
TALBERT, JAMES
|
FLORIDA ASSN OF PEDIATRIC TUMOR PROG
|
|
Reverse ChIP: Sequence-specific extraction of DNA-bound histones for analysis of
|
1R43CA159883-01A1
|
$295,222
|
$295,222
|
Dapprich, Johannes
|
GENERATION BIOTECH, LLC
|
|
GHSU Minority-Based Community Clinical Oncology Program
|
2U10CA107586-09
|
$492,552
|
$14,777
|
JILLELLA, ANAND
|
GEORGIA HEALTH SCIENCES UNIVERSITY
|
|
Quantitative and Spatial Optimization for Designing Cancer Therapeutics
|
1F32CA168274-01
|
$52,190
|
$26,095
|
Robinson-Mosher, Avram
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
|
Iowa Oncology Research Association
|
2U10CA035101-27
|
$669,579
|
$13,392
|
BEHRENS, ROBERT
|
IOWA ONCOLOGY RESEARCH ASSOCIATION
|
|
Quantitative SPECT for Targeted Radionuclide Therapy
|
5R01CA109234-07
|
$392,874
|
$98,219
|
FREY, ERIC
|
JOHNS HOPKINS UNIVERSITY
|
|
Tumor-produced TNF alpha as an inducer of immune resistance and tumor survival
|
5R01CA136663-03
|
$330,091
|
$330,091
|
Levitskaia, Elena
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
2P30CA006973-49
|
$6,995,267
|
$69,953
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-49S1
|
$75,000
|
$750
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-49S2
|
$50,000
|
$500
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Large-scale Genetic Analyses of Human Cancer
|
2R01CA121113-06
|
$279,212
|
$13,961
|
VELCULESCU, VICTOR
|
JOHNS HOPKINS UNIVERSITY
|
|
Topic 276-"Chemolieve: Differential protection of normal versus cancer cells in p
|
N44CO120051-000
|
$1,499,963
|
$299,993
|
MORGAN, TODD
|
L-NUTRA INC.
|
Total relevant funding to Neuroblastoma for this search: $27,138,562
|